SpyGlass Pharma Q2 FY26 net loss widens to $19.9 million; R&D expenses rise to $10.9 million

Reuters2026/08/06 20:37

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

SpyGlass Pharma posted a Q2 net loss of USD 19.9 million, or USD 0.59 per share, versus a loss of USD 8.7 million a year earlier.
RD expense climbed to USD 10.9 million from USD 7.3 million, due to the hiring of clinical personnel.
GA expense rose to USD 11 million from USD 2 million, on higher professional service fees and personnel costs.
Cash, cash equivalents and short-term investments totaled USD 234.2 million at June 30; funding expected to last through 2028.
Phase 3 BIM-IOL enrollment remains on track for completion in 2027; BIM-DRS first-in-human trial still slated for H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyglass Pharma Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

SpyGlass Pharma Q2 FY26 net loss widens to $19.9 million; R&D expenses rise to $10.9 million

You may also like

Crypto prices